Multicenter Study Grows Experience Optimizing Teclistamab for MM in Older Adults

Blood Cancers Today caught up with Krina Patel, MD, MSc, co-editor-in-chief for the BCT editorial board, about her recent clinical research work in multiple myeloma. Dr. Patel is based at the University of Texas MD Anderson Cancer Center in Houston, where she is the section chief and research lead for multiple myeloma, as well as an associate professor in the Department of Lymphoma and Myeloma.

Dr. Patel was involved in a real-world, multicenter US study of older adult patients who received teclistamab for relapsed or refractory multiple myeloma,¹ and in this interview segment, she explains its key findings. She describes how care and trial enrollment in this population carry special concerns about comorbidities and explains that the study yielded important insights about optimal teclistamab dosing to balance efficacy and side effects.

Noting the infection risk and side effects associated with bispecific antibodies such as teclistamab, Dr. Patel is still optimistic about the outcomes achievable with these agents so long as patients receive the necessary supportive care.